Skip to main content
OpenTrials
Completed

NCT Number: NCT06542965

Bloodstream Infection of Carbapenem-Resistant Proteus Mirabilis

This study aims to determine the clinical characteristics, risk factors, and resistance mechanisms of patients with carbapenem-resistant P. mirabilis bacteremia.Patients with P. mirabilis growth in blood culture samples sent to bacteriology laboratory between 2018 and 2021 were retrospectively analyzed. Patients meeting the inclusion criteria were divided into carbapenem-resistant and carbapenem- susceptible groups. The investigators recorded demographic data, clinical features, and laboratory findings. Resistance genes were investigated in carbapenem-resistant isolates using PCR.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Proteus Mirabilis Infection Bacteremia Bacterial Infections Bacterial Infections and Mycoses Carbapenem Resistant Bacterial Infection Infections Inflammation Pathologic Processes Pathological Conditions, Signs and Symptoms Sepsis Systemic Inflammatory Response Syndrome

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Dokuz Eylül University

Izmir, 35400, Turkey (Türkiye)

About this study

Patients with P. mirabilis growth in blood culture who met the study criteria were divided into two groups as carbapenem susceptible and resistant according to carbapenem antibiogram results. Patients with carbapenem-resistant P. mirabilis (CRPM) growth in blood culture were included in the case group and patients with carbapenem- susceptible P. mirabilis (CSPM) growth in blood culture were included in the control group.

Demographic characteristics of the patients, concomitant chronic diseases, Charlson comorbidity index (CCI), hospital and intensive care unit (ICU) hospitalization and number of days in the last year, history and type of invasive intervention in the last three months (surgical-invasive), history of antibiotic use in the last three months and types of antibiotics used (Penicillin, cephalosporin, quinolone, carbapenem, tigecycline, colistin, aminoglycoside), hospitalization unit, total length of hospitalization, sample collection unit, growth result and antibiogram, clinical and laboratory data of the day of growth, sepsis and septic shock evaluated according to systemic inflammatory response syndrome (SIRS) criteria, 30-day mortality and patient outcome information were recorded.

Carbapenemase-producing gene regions were investigated by Polymerase Chain Reaction (PCR) in accessible samples of patients with carbapenem-resistant P. mirabilis growth in blood cultures.

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Inpatients aged 18 years and older
  • P. mirabilis growth in blood cultures

Exclusion criteria

  • Samples taken in emergency departments, outpatient clinics, day treatment units
  • Recurrent growths of the same patient

Treatment and study plan

Non-Interventional Research

Other

Non-Interventional Research

Primary outcomes

  1. Carbapenem Use

    Time frame: 1 year

    number of patients using carbapenem before P. mirabilis growth in blood cultures

  2. Intensive Care Units

    Time frame: 1 year

    number of patients admission in ıntensive care units before P. mirabilis growth in blood cultures

  3. Mortality

    Time frame: 30 days

    number of patients who died

  4. Length of hospital stay

    Time frame: 1 year

    Length of hospital stay days

  5. Presence of chronic disease

    Time frame: 1 year

    number of patients with chronic disease

Sponsors and collaborators

Lead sponsor

Dokuz Eylul University

Other

Registry information

Official study title

Clinical Characteristics, Risk Factors and Resistance Mechanisms for Bloodstream Infection of Carbapenem-Resistant Proteus Mirabilis

Important dates

Study start
2018
Primary completion
2021
Study completion
2023
First posted
Aug 7, 2024
Registry last updated
Aug 7, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.